Enhanced expression of full-length human cytomegalovirus fusion protein in non-swelling baculovirus-infected cells with a minimal fed-batch strategy

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Patrone, Marco ^a,d   Carinhas, Nuno ^a,b   Sousa, Marcos Q ^a   Peixoto, Cristina ^a   Ciferri, Claudio ^c,e   Carfì, Andrea ^c   Alves, Paula M ^a,b  

^a INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLÓGICA   (Portugal)

^b INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA   (Portugal)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; RAPAMYCIN; UNCLASSIFIED DRUG; VIRUS FUSION FACTOR GLYCOPROTEIN B; VIRUS FUSION PROTEIN;

ARTICLE; BACULOVIRUS; BACULOVIRUS EXPRESSION SYSTEM; BACULOVIRUS INFECTION; CELL DENSITY; CELL SIZE; CELL SWELLING; CELL VIABILITY; CELL VOLUME; DEGLYCOSYLATION; DNA VIRUS INFECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN STABILITY; SPODOPTERA FRUGIPERDA; VIROGENESIS; VIRUS LOAD;

ANIMALS; BACULOVIRIDAE; BIOREACTORS; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GENE EXPRESSION; GENES, VIRAL; HUMANS; INSECTS; MODELS, MOLECULAR; RECOMBINANT PROTEINS; VIRAL FUSION PROTEINS;

EID: 84897095032     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090753     Document Type: Article

References (37)

1. Britt W (2008) Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr Top Microbiol Immunol 325: 417-470.
2. (2000) Vaccines for the 21st Century: A Tool for Decision making. The National Academies Press.
3. (2010) Priorities for the National Vaccine Plan. The National Academies Press. 9780309146531 9780309146531.
4. Heldwein EE, Krummenacher C (2008) Entry of herpesviruses into mammalian cells. Cell Mol Life Sci 65: 1653-1668.
5. Atanasiu D, Saw WT, Cohen GH, Eisenberg RJ (2010) Cascade of events governing cell-cell fusion induced by herpes simplex virus glycoproteins gD, gH/gL, and gB. J Virol 84: 12292-12299.
6. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, et al. (2009) Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360: 1191-1199.
7. Dempsey AF, Pangborn HM, Prosser LA (2012) Cost-effectiveness of routine vaccination of adolescent females against cytomegalovirus. Vaccine 30: 4060-4066.
8. Patrone M, Secchi M, Bonaparte E, Milanesi G, Gallina A (2007) Cytomegalovirus UL131-128 products promote gB conformational transition and gB-gH interaction during entry into endothelial cells. J Virol 81: 11479-11488. (Pubitemid 47536118)
9. Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, et al. (2004) Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78: 10023-10033. (Pubitemid 39187120)
10. Wang D, Shenk T (2005) Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A 102: 18153-18158. (Pubitemid 41798517)
11. Ryckman BJ, Rainish BL, Chase MC, Borton JA, Nelson JA, et al. (2008) Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 82: 60-70. (Pubitemid 350309123)
12. Heldwein EE, Lou H, Bender FC, Cohen GH, Eisenberg RJ, et al. (2006) Crystal structure of glycoprotein B from herpes simplex virus 1. Science 313: 217-220. (Pubitemid 44066251)
13. Dollery SJ, Wright CC, Johnson DC, Nicola AV (2011) Low-pH-dependent changes in the conformation and oligomeric state of the prefusion form of herpes simplex virus glycoprotein B are separable from fusion activity. J Virol 85: 9964-9973.
14. Silverman JL, Greene NG, King DS, Heldwein EE (2012) Membrane requirement for folding of the herpes simplex virus 1 gB cytodomain suggests a unique mechanism of fusion regulation. J Virol 86: 8171-8184.
15. Silverman JL, Heldwein EE (2013) Mutations in the Cytoplasmic Tail of Herpes Simplex Virus 1 gH Reduce the Fusogenicity of gB in Transfected Cells. J Virol 87: 10139-10147.
16. Lopper M, Compton T (2002) Disulfide bond configuration of human cytomegalovirus glycoprotein B. J Virol 76: 6073-6082. (Pubitemid 34556302)
17. Britt WJ, Vugler LG (1989) Processing of the gp55-116 envelope glycoprotein complex (gB) of human cytomegalovirus. J Virol 63: 403-410. (Pubitemid 19028121)
18. Fernandes F, Teixeira AP, Carinhas N, Carrondo MJ, Alves PM (2013) Insect cells as a production platform of complex virus-like particles. Expert Rev Vaccines 12: 225-236.
19. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, et al. (2012) Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13: 89-99.
20. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, et al. (2011) Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 29: 7733-7739.
21. Backovic M, Longnecker R, Jardetzky TS (2009) Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B. Proc Natl Acad Sci U S A 106: 2880-2885.
22. Sharma S, Wisner TW, Johnson DC, Heldwein EE (2013) HCMV gB shares structural and functional properties with gB proteins from other herpesviruses. Virology 435: 239-249.
23. Backovic M, Jardetzky TS (2009) Class III viral membrane fusion proteins. Curr Opin Struct Biol 19: 189-196.
24. Hahn G, Khan H, Baldanti F, Koszinowski UH, Revello MG, et al. (2002) The human cytomegalovirus ribonucleotide reductase homolog UL45 is dispensable for growth in endothelial cells, as determined by a BAC-cloned clinical isolate of human cytomegalovirus with preserved wild-type characteristics. J Virol 76: 9551-9555. (Pubitemid 34919913)
25. Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, et al. (2010) Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39: 171-183.
26. Jewell JL, Guan KL (2013) Nutrient signaling to mTOR and cell growth. Trends Biochem Sci 38: 233-242.
27. Balcarcel RR, Stephanopoulos G (2001) Rapamycin reduces hybridoma cell death and enhances monoclonal antibody production. Biotechnol Bioeng 76: 1-10. (Pubitemid 33081199)
28. Radford KM, Reid S, Greenfield PF (1997) Substrate limitation in the baculovirus expression vector system. Biotechnol Bioeng 56: 32-44. (Pubitemid 27382484)
29. Britt WJ, Vugler LG (1992) Oligomerization of the human cytomegalovirus major envelope glycoprotein complex gB (gp55-116). J Virol 66: 6747-6754.
30. Carinhas N, Bernal V, Monteiro F, Carrondo MJ, Oliveira R, et al. (2010) Improving baculovirus production at high cell density through manipulation of energy metabolism. Metab Eng 12: 39-52.
31. Monteiro F, Bernal V, Saelens X, Lozano AB, Bernal C, et al. (2013) Metabolic profiling of insect cell lines: Unveiling cell line determinants behind system's productivity. Biotechnol Bioeng accepted.
32. Chauvin C, Koka V, Nouschi A, Mieulet V, Hoareau-Aveilla C, et al. (2013) Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. Oncogene.
33. Martin S, Saha B, Riley JL (2012) The battle over mTOR: an emerging theatre in host-pathogen immunity. PLoS Pathog 8: e1002894.
34. Bender FC, Whitbeck JC, Ponce de Leon M, Lou H, Eisenberg RJ, et al. (2003) Specific association of glycoprotein B with lipid rafts during herpes simplex virus entry. J Virol 77: 9542-9552. (Pubitemid 37011049)
35. Strive T, Borst E, Messerle M, Radsak K (2002) Proteolytic processing of human cytomegalovirus glycoprotein B is dispensable for viral growth in culture. J Virol 76: 1252-1264. (Pubitemid 34066429)
36. Schleiss MR, Jensen NJ (2003) Cloning and expression of the guinea pig cytomegalovirus glycoprotein B (gB) in a recombinant baculovirus: utility for vaccine studies for the prevention of experimental infection. J Virol Methods 108: 59-65. (Pubitemid 36143850)
37. Pass RF, Duliege AM, Boppana S, Sekulovich R, Percell S, et al. (1999) A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 180: 970-975. (Pubitemid 30070176)